by Nathaniel Harding | Apr 26, 2024 | Blog
Sensulin Biotech, an Oklahoma startup, is bringing the lowest-cost Smart Insulin to the market. Mike Moradi, CEO of Sensulin and General Partner of Cortado Ventures, aims to reduce the burden of diabetes and change lives by creating innovative opportunities for their...
by Nathaniel Harding | Mar 25, 2024 | Blog
In an industry where women are still significantly underrepresented with women representing just 8.6% of all venture capitalists and 8% of firm partners across the country, and VC-backed startups founded solely by women still coming in at a paltry 2%, Women’s History...
by Nathaniel Harding | Mar 11, 2024 | Blog
Cortado Ventures is thrilled to have recently invested in Cadenza Bio, an Oklahoma life sciences company developing novel therapeutic drugs to treat demyelinating, inflammatory, and neurodegenerative diseases, with a first indication in multiple sclerosis (MS). Read...
by Nathaniel Harding | Feb 22, 2024 | Blog
A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad Cortado is thrilled to invest in CorriXR Therapeutics, an early-stage biotech company commercializing a platform gene editing technology with a first-use case in oncology. The novel approach seeks to...
by Nathaniel Harding | Feb 5, 2024 | Blog, Media
Lumata Health: Pioneering Next-Generation Eye Care At Cortado Ventures, we are in the venture capital business of maximizing risk-adjusted returns with high-potential, early-stage startups. We seek transformative technology solutions with as little risk as possible....
by Nathaniel Harding | Feb 1, 2024 | Blog
2023 Lookback for Cortado Ventures At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and most innovative startups. Let’s...